Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALN1001
- Development stage
- Preclinical
- Lead developer
- Alaunos Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALN1001 is an orally available, non-hormonal small molecule currently in preclinical development for the treatment of obesity. Developed by Alaunos Therapeutics (formerly Ziopharm Oncology), the program represents a strategic expansion for the company into metabolic health, leveraging a mechanism of action that is distinct from the incretin-based (GLP-1/GIP) therapies currently dominating the weight-loss market. While specific molecular targets remain undisclosed, the asset is part of a broader effort to provide alternative pharmacological options for weight management. As of early 2025, the program remains in the preclinical phase of development.
Beyond the preview
Go deeper on ALN1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALN1001.